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INTRODUCTION 
Tumor development is a multi-step process dur-
ing which genetic and epigenetic events determine 
the transition from normal to malignant cellular 
state. Apart from the fact that tumor cells bear an 
indefinite proliferative capacity, they also show acti-
vation of the signaling pathways that are involved in 
the transduction of mitogenic stimuli. This activation 
is either due to overexpression or mutation of signal 
transduction molecules. Such an example is the 
activating ras mutations, which are present in 30% 
of the human tumors and result in persistent signal 
transduction via the MAP kinase pathway, the PI-3 
kinase pathway and possibly other downstream 
effector pathways. 
In order to investigate the role of AP-1 transcrip-
tion factor in carcinogenesis, as well as to identify a 
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potential link between the AP-1, GR and ER factors 
during this process, we have used a multistage 
mouse skin carcinogenesis model. This model is 
ideal for the study of questions related to the timing 
of oncogene activation and inactivation of the tumor 
suppressor genes. For the induction of carcino-
genesis the most common regimen was followed, 
which involves administration on the mouse epi-
dermis of a single dose of the polycyclic aromatic 
hydrocarbon, dimethyl benzanthracene (DMBA), 
followed by weekly applications of the phorbol ester 
TPA (12-0-tetradecanoylphorbol-13acetate). Nu-
merous benign papillomas appeared, a proportion 
of which progressed to malignant carcinomas within 
20-40 weeks after the first exposure to the chemical 
carcinogens. We have selected five cell lines from 
different stages of mouse skin tumor progression. 
These include immortalised, non-tumorigenic cell 
lines (C5N), benign papilloma (P1), squamous car-
cinoma (B9) cell lines and highly anaplastic, inva-
sive spindle cell lines with highly metastatic proper-
ties (A5 and CarB). These cell lines are representa-
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tive of the three distinct stages in mouse carcino­
genesis (initiation, promotion and progression). 
The initiation and progression of mouse skin car­
cinogenesis is related to mutations in specific 
genes, which could endow these genes with trans­
forming properties. A. Balmain carried out a series 
of studies, which led to the identification of a single 
gene, the Η-ras gene (of the ras family), as a gene 
which is consistently mutated after application of 
DMBA (2). Over 90% of tumors, showed mutations 
at the middle adenosine residue at codon 61 (CAA) 
of Η-ras gene, which resulted in conversion to 
thymidine (CTA) and in the introduction of an acti­
vated missense mutation (2,3). The proof that this 
gene is implicated in the initiation of mouse skin 
carcinogenesis came in 1986 by Brown and Bal­
main, who showed that the retroviruses carrying 
activated Η-ras gene when applied to the skin', 
could replace chemical induction by DMBA in vivo 
(4). 
It has already been shown that during tumor pro­
gression, genetic changes lead to altered ratio of 
normal to mutated Η-ras alleles (5). Such changes 
involved non-disjunction of chromosome 7 or mi­
totic recombination leading to homozygosity at the 
distal part of this chromosome. FISH analysis, 
which was carried out in A. Balmain's laboratory, 
revealed that indeed there is an altered ratio of 
normal/mutant Η-ras in the mouse skin cell lines. 
Furthermore, they identified two normal and four 
mutated alleles in the B9 squamous carcinoma cell 
line, one normal and two mutated alleles in the 
spindle A5 cell line and only mutated Η-ras alleles 
in the spindle CarB cell line. FISH analysis showed 
additionally that double-minute chromosomes, in 
which the Η-ras gene is located, are present in the 
A5 cell line. 
ONCOGENE AND ONCO-SUPPRESSOR GENE 
STATUS IN THE MOUSE SKIN SYSTEM 
In our laboratory, we have used the same cell 
lines to investigate whether these genetic changes 
that lead to altered ratio of normal to mutant H-ras 
at DNA and RNA levels, were reflected to corre­
sponding changes in the protein expression. In­
deed, in Table I, lines 1 and 2, it can be seen that 
there is a different expression of normal and mutant 
Η-Ras proteins between the cell lines, which corre­
sponds to the altered ratio of normal/mutant H-ras 
alleles (6). While C5N immortalised cells expresses 
only normal Η-Ras protein,' in papilloma and 
squamous carcinomas, the balance shifts in favour 
of the mutant allele of H-ras gene. In some spindle 
carcinoma cell lines, a further increase in expres­
sion has been achieved by localised amplification of 
the mutant H-ras, while in other cases, they have 
lost the normal allele (cell lines A5 and CarB re­
spectively) (Table 1, Ref 6). 
Table 1 
Qualitative and quantitative changes of AP-1 GR and ER 
factors during mouse skin carcinogenesis. 'Method, 
'Molecule,JOligonucleotide, 'Reporter Plasmid, 'Western 
Blot, 'Retardation Assay, 7Luciferase Assay 
Melh'/Mof/Olig'/RP' 
WB 5 /N- R a s / - / -
W 8 S /M- Ras / - / -
W B / c - j u n / - / -
W B / p - c - j u n / - / -
W B / j u n B / - / -
W B / j u n D / - / -
WB / c-los / - / -
W B / F r a - 1 / - / -
WB / Fra-2 / - / -
WB / ATF-2 / - / -
W B / p - A T F - 2 / - / - 1 . 0 
W B / J N K 1 / - / -
W B / J N K 2 / - / 
JNK - assay 
R A V A P - 1 / C O I I I I T R E / -
RA/AP-1/jun2TRE/-
LA7/AP-1/-/5xcoHTRE 
LA/AP-1/-/5xjun2TRE 
W B / E R / - / -
RA/ ER/ vit ERE/ -
C50 
2.0 
0 
LO 
1.0 
1.0 
CELL 
Pi 
LO 
2.0 
1.1 
B9 
2.0 
3.0 
2.53 
1.54 2.62 
1.16 6.8 
1.0 0.82 0.95 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
2.4 
1.1 
2.5 
2.2 
2.8 
1.2 
1.3 
1.1 
2.1 
0.9 
2.0 
2.5 
2.6 
2.3 
5.8 
7.9 
2.1 
2.0 
3.5 
4.6 
4.2 
3.78 
1.11 4.31 
1.2 
1.0 
1.2 
3.0 
LINES 
A5 
2.0 
4.0 
2.81 
5.4 
2.0 
1.05 
5.0 
2.2 
2.5 
4.5 
9.1 
4.25 
8.2 
3.2 
7.7 
5.1 
4.33 
5.14 
7.0 
6.0 
CarB L 
0 
2 
3.8 
6.45 
3.0 
0.86 
4.5 
2.9 
3.0 
5.1 
12.0 
4.0 
.0 
3.2 
7.6 
5.6 
4.66 
6.0 
7.6 
5,5 
.ine No 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Mutations in other genes apart from H-ras are 
also found in the mouse skin carcinogenesis model 
and are also implicated in tumor progression. Muta­
tions in the gene encoding p53 oncosuppressor 
protein are present in more than half of human can­
cers. The majority of these mutations are point mis-
sense mutations at the DNA binding domains of the 
protein that inactivate p53 function as a transcrip-
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tion factor. In normal cells, p53 levels are increased 
due to DNA damage and/or other stresses. These 
increased levels cause dramatic cellular responses, 
such as cell cycle arrest, senescence and apop-
tosis. Recent studies have shown that the key ele­
ment for the control of p53 response is the Mdm2 
protein, which exhibits a unique relationship with 
p53 (7). It has been identified in the mouse car­
cinogenesis system that loss of heterozygosity 
(LOH) is present at the p53 locus in one third of the 
carcinomas. Furthermore, sequencing analysis of 
the remaining allele of p53 in the B9 and A5 cell 
lines showed that two mutations are present at 
codons 236 TGC->TTC and 246 CTT-> CTA (8). 
Many members of the cyclin family have been 
implicated in the etiology of various types of human 
tumors (9). Specifically, cyclin D1 is a protein which 
is active in G1 phase and it forms a complex with 
cyclin dependent kinases'4 and 6 in order (o be 
activated. Their function is negatively regulated by 
a series of inhibitors including p15, p16, p21 and 
p27. Overexpression of cyclin D1 leads to shorter 
G1 period resulting in increased proliferation. In 
keratinocytes, cyclin D1 expression and the activity 
of its associated kinases are upregulated in re­
sponse to oncogenic ras. Also in the mouse skin 
carcinogenesis system cyclin D1 levels are higher 
in carcinomas than in papillomas and its regulation 
by ras may be transcriptional through the regulation 
of AP-1 (6,10). 
Qualitative changes in the expression of the Rb 
and p16 oncosuppressor proteins are also present 
during progression of mouse skin carcinogenesis. 
The amount of Rb protein is unaffected during cell 
cycle progression, while the phosphorylation state 
of Rb is cycle-dependent. pRb is in an uderphos-
phorylated form in G 1 , and as the cell progresses 
into late G1 and early S phase, it becomes hyper-
phosphorylated and is maintained in G2. Some 
studies in human squamous tumors have impli­
cated p16 in the immortalisation step of tumor de­
velopment (11). In contrast, in mouse skin tumors, 
as well as in human brain tumors and others, a 
positive correlation has been found between 
p16/INK4 alterations and the later events in pro­
gression (12). In the majority of spindle carcinoma 
cell lines isolated from mouse skin, i.e. eight out of 
ten, the INK4 locus was found to be homozygously 
deleted, while in all of the 20 squamous cell lines 
studied, the INK4 locus was found to be intact (12). 
AP-1 COMPONENTS DURING TUMOR 
DEVELOPMENT IN MOUSE SKIN 
Oncogenic Ras proteins have been shown to 
regulate AP-1 activity at transcriptional and post-
transcriptional levels. Among the jun family genes 
that encode for transcription factors, only c-jun dis­
plays full transformation potential in cooperation 
with activated Η-ras in primary embryo fibroblasts 
(13). Phosphorylation of N-terminal c-Jun protein' 
residues Ser-63 and Ser-73 by JNK kinases is nec­
essary for transactivation and oncogene coopera­
tion, as shown by in vitro transformation assays. 
Jun Β and Jun D can also cooperate with Ras to 
induce foci, but with lower efficiency when com­
pared to c-Jun (14). Among the Fos protein mem­
bers it has been shown that Fra-2 plàys a crucial 
role in the transformation induced by Η-ras gene in 
CEF, while Fra-1 induces morphological transfor­
mation of mouse adenocarcinoma cells and c-Fos 
expression is involved in benign-to-malignant tumor 
progression (15-17). 
We investigated the role of AP-1 family members 
in progression of mouse skin cancer. It was de­
tected that there is increased expression of c-Jun in 
the tumorigenic cell lines, with maximum increase 
in the spindle cell lines A5 and CarB (line 3). The 
same pattern of increase was also detected in the 
expression of the phosphorylated form of c-Jun, as 
can be seen in Table I line 4. Analysis of the other 
Jun family members by Western blotting revealed 
that, whilst the levels of Jun D (lane 6) remained 
more or less stable in all cell lines, increased Jun Β 
levels were found only in the B9 cell line (lane 5). 
This result indicates that Jun Β overexpression may 
play a specific role in the formation of the 
squamous carcinoma phenotype. Western blot 
analysis was also carried out for c-Fos, Fra-1 and 
Fra-2 and it was shown that hyperphosphorylated 
Fra-1 exists in high levels in the cell lines with ma­
lignant phenotypes, B9, A5 and CarB (line 8). On 
the other hand, c-Fos and Fra-2 were found to be 
elevated in the same cell lines, as well as in the 
papilloma cell line P1 (lines 7 and 8 respectively) 
compared to the immortalised C5N cells. ATF-2 
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protein was also investigated and it was found to be 
elevated in the papilloma cell line P1, and highly 
increased in the malignant cell lines, B9, A5 and 
CarB (line 10). The same was demonstrated also 
for the phosphorylated form of ATF-2 (line 11). 
It was also shown that there are increased 
amounts of JNK 1 and JNK 2 kinases in the malig-
nant cell lines compared to the immortalised cells 
(lines 12 and 13). However, JNK 2 is increased to a 
more modest extent than JNK 1. In order to extend 
the validity of this result, we analysed the endoge-
nous in vitro kinase activity of JNK using GST-c-jun 
as substrate, and a similar increase was detected 
as in the Western blot analysis. Since Ras-acti-
vated members of the JNK subgroup of MAPKs are 
the major mediators of c-Jun and ATF-2 aminoter-
minal phosphorylation (18), the increased levels of 
' JNKs which were detected in the mouse skin, are 
correlated with qualitative and quantitative changes 
of c-Jun and ATF-2 proteins (6). From the analysis 
presented above, it can be seen that altered ex-
pression and post-translational modifications of the 
AP-1 family members are present in the mouse skin 
cell lines. In order to investigate whether these 
changes result in the AP-1 DNA binding activity, 
electromobility shift assays were performed. The 
DNA-binding activity was found to be slightly in-
creased in the papilloma cell line P1, further ele-
vated in the B9 squamous carcinoma cell line, and 
peaked in the metastatic cell lines A5 and CarB 
(Table I line 15, 16). Luciferase activity was also 
found to be elevated in these cell lines (line 17, 18). 
Also, it was observed that there is increased c-
Jun/ATF-2 binding activity in the malignant cell 
lines, compared to the immortalised cell line (line 
8). 
THE IMPLICATION OF STEROID HORMONE 
RECEPTORS IN MOUSE SKIN CARCINOGENESIS 
Glucocorticoid hormones are known to serve a 
variety of important functions in eukaryotic cells and 
tissues. Usually, glucocorticoids promote cell differ-
entiation and inhibit proliferation. For example, 
these hormones are known to inhibit DNA synthesis 
in normal keratinocytes in vivo (19). Studies have 
demonstrated that glucocorticoids prevent phorbol-
ester-induced inflammation and skin hyperplasia 
(19, 20). Glucocorticoids are very potent inhibitors 
of skin tumor formation, especially during tumor 
promotion. , , 
The cellular response to glucocorticoids is mediated 
through a highly specific cytoplasmic glucocorticoid 
receptor (GR). Upon activation by ligand binding, 
GR forms a homodimer and migrates to the nucleus 
of the cell, where it binds to specific DNA se-
quences called glucocorticoid-response elements 
(GREs) (21). The vast majority of GREs have a 
unique'Structure; they are palidromic sequences of 
15 bp that have been shown to bind a GR dimer 
and to work as typical enhancers of transcription 
(20). 
The expression of estrogen receptors has been 
examined. As it can be seen in Table I line 19, 
Western blot analysis indicated that there is over-
expression 'ÉR in the spindle cell lines A5 and 
CarB, compared to the immortalised cell line C5N. 
This increase indicates that these receptors are 
activated in the malignant cell lines with metastatic 
properties. Furthermore, after DNA-binding analysis 
by electromobility shift assay, it was detected that 
there is increased DNA-binding on the specific ERE 
sequences in the same cell line (lanes 20), (Zoum-
pourlis et al., manuscript in preparation). 
CROSS-TALK BETWEEN AP-1 AND STEROID 
HORMONE RECEPTORS 
In contrast to the unique mechanism of gene 
upregulation by glucocorticoids, through GRE ele-
ments, several different mechanisms for gene re-
pression by GR have been described. These 
mechanisms include competition of GR with other 
transcription factors for the DNA-binding sites or 
with common mediators for the transcriptional-ini-
tiation complex (21,23-26). This is also evidence of 
negative cross-talk on the protein-protein level be-
tween GR and such nuclear transcriptional factors 
as AP-1 and inflammation responsive factor N F K B 
(21,24,27). Thus, genes whose activity is controlled 
by AP-1 or N F K B may be downregulated by gluco-
corticoids through inhibition of these factors. The 
genes that are inhibited by glucocorticoids include 
prolactin, collagenase type I, stromelysin, GR itself, 
and some other genes (reviewed in 28). Ultimately, 
the activation of GR by glucocorticoid hormones 
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results in activation or repression of the network of 
glucocorticoid-responsive genes and produces a 
specific cellular response. 
CONCLUSIONS 
After the investigation of c-Jun, Fra-1, Fra-2, ATF-
2, GR and ER molecules, in this mouse skin model, 
it was concluded that these proteins play a role in 
the progression of carcinogenesis, since they were 
detected at high amounts in the cell lines with ma-
lignant phenotypes. The quantitative and qualitative 
changes in the AP-1 components is probably due to 
the increased amounts of Ras protein, which is 
overexpressed in these cells (6). These results are 
in agreement with previous studies, which note that 
Ras-mediated transformation activates AP-1 tran-
scription (22). Furthermore, we confirm that ATF-2, 
together with c-Jun and Fra proteins, appear to he 
the major components of AP-1 complex in cycling 
keratinocytes and they are further activated in 
transformed cells. Additionally we showed for the 
first time, that dominant negative ATF-2 inverts the 
spindle carcinoma phenotype to squamous-like. 
These results indicate the implication of ATF-2 
transcription factor at late stages of mouse skin 
carcinogenesis (Zoumpourlis et al., manuscript in 
preparation) 
Studies of skin carcinogenesis have shown that 
different target genes exert their functions at differ-
ent stages of carcinogenesis. The human equiva-
lent of these genes may be useful for the prediction 
of individual cancer risk, and for the development of 
approaches to cancer prevention and therapy. The 
analysis of AP-1 oncogenic components and ster-
oid hormone receptors cross-talking partners in the 
multistage carcinogenesis system, provide us the 
tools for the study of the role of hormone agonists 
and antagonists in cancer therapy. 
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